BioTuesdays

Category - Markets

IRadimed

Roth ups IRadimed PT to $35 from $26

Roth Capital Partners raised its price target for IRadimed (NASDAQ:IRMD) to $35 from $26 after updating its forward financial forecasts. The stock closed at $31.40 on Sept. 19. IRadimed is the world’s first and...

AVROBIO

HCW starts AVROBIO at buy; PT $47

H.C. Wainwright initiated coverage of AVROBIO (NASDAQ:AVRO) with a “buy” rating and $47 price target. The stock closed at $39.63 on Sept. 13. AVROBIO is pioneering the development of lentiviral gene therapies as a...

Mersana Therapeutics Logo

HCW ups Mersana Therapeutics PT to $23 from $16

H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $23 from $16 after the company disclosed plans to reinstate dosing of new patients following the FDA decision to lift the partial...

UroGen Pharma

Stifel starts UroGen Pharma at buy; PT $70

Stifel initiated coverage of UroGen Pharma (NASDAQ:URGN) with a “buy” rating and $70 price target. The stock closed at $43.90 on Sept. 12. “We think UroGen offers investors an opportunity to own a company with a late...

Rocket Pharmaceuticals Logo

Ladenburg starts Rocket Pharma at buy; PT $30

Ladenburg Thalmann launched coverage of Rocket Pharmaceuticals (NASDAQ:RCKT) with a “buy” rating and $30 price target. The stock closed at $23.96 on Sept. 12. Rocket is developing potentially curative first-in-class...

rhythm pharmaceuticals

Stifel starts Rhythm Pharma at hold; PT $36

Stifel launched coverage of Rhythm Pharmaceuticals (NASDAQ:RYTM) with a “hold” rating and $36 price target, saying the risk/reward for the shares is pretty balanced at current levels. The stock closed at $30.77 on Sept...

Vanda Pharmaceuticals

Stifel starts Vanda Pharma at buy; PT $30

Stifel initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a “buy” rating and $30 price target. The stock closed at $18.45 on Sept. 12. “We like the near-term catalyst path for Vanda shares as we believe...

ObsEva Logo

JP Morgan starts ObsEva at OW; PT $29

J.P. Morgan launched coverage of ObsEva SA (NASDAQ:OBSV) with an “overweight” rating and a price target of $29 at the end of 2019. The stock closed at $14.40 on Sept. 12. “We view ObsEva as an underappreciated, emerging...

Arch Therapeutics

Ladenburg stars Arch Therapeutics at buy; PT $1.25

Ladenburg Thalmann initiated coverage of Arch Therapeutics (OTCQB:ARTH) with a “buy” rating and price target of $1.25. The stock closed at 46 cents on Sept. 11. The company is developing a novel hemostat to control skin...

Novus Therapeutics

Ladenburg starts Novus Therapeutics at buy; PT $12

Ladenburg Thalmann launched coverage of Novus Therapeutics (NASDAQ:NVUS) with a “buy” rating and $12 price target. The stock closed at $4.53 on Sept. 10. Novus is developing a novel treatment for otitis media (OM)...